Clinical prostate cancer and human prostate cancer cell lines |
Increasing |
Increasing (effect is in the early stage of initiation) |
[7, 8, 12, 13, 35, 36] |
Mouse prostate carcinomas in TRAMP mice |
Increasing |
Increasing |
[41] |
Clinical melanoma and human melanoma cell lines |
No effect |
Increasing (effect is in the late stages) |
[3, 20] |
Mouse melanoma cell line of K1735 subline number 3 and 10s |
No effect or slight suppression |
Increasing (effect is in the late stages) |
[9, 21] |
Mouse melanoma cell line K1735 subline number 9 |
Suppression |
Suppression |
[22, 23] and Wu et al. unpublished results |
Angiosarcoma |
Increasing |
Not determined |
[7, 37] and Wu et al. unpublished results |
Human ovarian cancer cell lines BG-1 and SK-OV-3 |
Suppression |
suppression |
[33, 34] |
Human osteosarcoma cell lines |
Not determined |
Increasing |
[39] |
Human breast cancer cell line MCF-7 |
Suppression |
Not determined |
[24] |
Human breast cancer cell lines MCF-7 and SK-BR-3 |
Increasing |
Not determined |
[30, 31] |
Haemangiomas |
Suppression? |
Not determined |
[38] |
Nasopharyngeal carcinoma |
Suppression? |
Not determined |
[7, 11] |